Mozobil (plerixafor)
- Region
- 🇪🇺 EU
- Active substance
- plerixafor
- Company
- Sanofi B.V.
- Status
- Authorised
- Therapeutic area
- Multiple Myeloma; Hematopoietic Stem Cell Transplantation; Lymphoma
- CHMP opinion
- Fri 29 May 2009
- EU approval
- Thu 30 Jul 2009
- Application
- EMEA/H/C/001030
- ATC
- L03AX16
- Official record
- www.ema.europa.eu
Indication
Mozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Plerixafor Accord Authorised · Accord Healthcare S.L.U.
Follow Mozobil
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.